Compound ID | 2886
SNIPR001
Class: Bacteriophage and/or bacteriophage-derived product
| Agent Type: | Natural product; Bacteriophage or bacteriphage-derived product; |
| Spectrum of activity: | Gram-negative |
| Target Pathogen: | Active against Escherichia coli |
| Description: | Engineered CRISPR-Cas cocktail containing four CRISPR–Cas-armed phages |
| Institute where first reported: | SNIPR Biome Aps. |
| Year first mentioned: | 2023 |
| Highest development stage: | Phase 1 (NCT05277350) |
| Development status: | Active as of 2024 |
| External links: | |
| Citation: | https://www.nature.com/articles/s41587-023-01759-y |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.